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Do new biologics meet the unmet medical need
in rheumatoid arthritis? Safety and efficacy of
abatacept following B-cell depletion
SIR, anti TNF-a agents (aTNFs) are the most commonly
prescribed biological agents in RA. More recently abata-
cept (ABA), a T-cell costimulation modulator, and rituxi-
mab (RTX), a monoclonal antibody directed against CD20,
have become available. Observational studies suggest
that switching to a new drug class may be more effective
in uncontrolled RA than switching to a class of biologics to
which the patient had unsuccessfully been exposed [1].
Information about the efficacy and safety of cycling stra-
tegies through third-line biologics is lacking. This study
aimed to analyse the effectiveness and safety of switching
patients to ABA as the third biological class after failure of
aTNF plus RTX.
The Swiss Clinical Quality Management (SCQM)
programme for RA is a longitudinal population-based
cohort, which has been approved by the local ethics com-
mittees of all participating centres [2]. For this analysis,
we collected all the cases of RA with an inadequate
response to at least one aTNF plus RTX, followed by
ABA. As our programme is mainly aimed at efficacy
data, an additional chart review for severe adverse
events (SAEs) was performed in all cases. We analysed
the evolution of 28-joint DAS (DAS-28) using mixed linear
models for longitudinal data [3].
By March 2009, 28 of 5056 SCQM patients met
the inclusion criteria. Patients had an average of 6.3 as-
sessments during a median follow-up of 22.1 months
[interquartile range (IQR) 17.4–31.3 months]. All patients
discontinued RTX because of insufficient disease control.
The key demographic, disease- and treatment-related
characteristics of patients are provided in Table 1.
The mean DAS-28 did not improve significantly over
time (mean improvement at 6 months 0.38 DAS units,
P¼ 0.48). Only six ABA patients (21%) had a clinically
meaningful DAS-28 improvement (0.6 units) after
6 months. However, the mean daily prednisone dose
was 2.1 mg lower compared with baseline (P¼ 0.01).
ABA was discontinued in 16 patients after a median
drug retention of 10.1 months (IQR 4.3–12.0 months).
ABA was discontinued within the first 6 months in eight
patients (six due to lack of improvement or clinical wor-
sening, one due to liver enzyme elevation and one due to
the patient’s desire).
SAEs during ABA included pneumonia (two patients),
erysipelas with bursitis, shingles, urinary tract infection
requiring antibiotics and rash (one patient each), yielding
an AE rate of 2.83/100 patient-years. The patient with
erysipelas was admitted for antibiotics. There was no op-
portunistic infection and no permanent damage.
Meta-analyses of randomized placebo-controlled trials
do not suggest an increased risk of serious infections with
RTX or ABA in comparison with placebo when given either
as first biologic, or after aTNF [4]. These meta-analyses
were, however, underpowered and also unable to provide
information of an added risk of previous biological treat-
ment. In RA patients on treatment with biological agents,
the addition of ABA was associated with an increase in
serious infections [5]. Genovese et al. [6] have previously
collected safety but not efficacy data of patients treated
with biological agents following RTX, 25 of whom received
ABA. In this analysis, the rate of serious infectious events
did not increase with the new biologic agent compared
with before exposure.
Our analysis is clearly limited by its observational nature
and the small sample size. Nevertheless, our data set rep-
resents the largest analysis so far of patients with ABA
after RTX. Our data add to the existing safety data but
suggest that the efficacy of ABA as a third-line biologic
is limited after failure of aTNF plus RTX. Thus, failure in
response to aTNF and RTX identifies a difficult-to-treat RA
population whose needs are currently not met and should
become a focus of clinical trials.
Rheumatology key message
. RA patients respond poorly to abatacept as the
third class of biological agents.
TABLE 1 Demographic and disease characteristics of RA
patients at the time of switch from RTX to ABA
Patient and RA characteristics
n 28
Female, n (%) 20 (71.4)
Age, mean (S.D.), years 61.2 (11.4)
DAS-28 at switch from RTX, mean (S.D.) 4.7 (2.5)
RA duration, mean (S.D.), years 13.2 (9.2)
RF positive, % 71.4
CCP positive, % 78.6
Number of biologics before RTX, mean 1.8
Months between RTX and ABA, mean (S.D.) 11.7 (7.0)
Patients on glucocorticosteroids, % 77.8
Prednisone equivalent, mean (S.D.), mg 8.3 (5.8)
Concomitant DMARD treatment
MTX or leflunomide, % 20 (83.3)
Other non-biologic DMARDs, % 2 (8.3)
No DMARDs, % 6 (21.4)
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